Gujarat Themis Biosyn Ltd

Guj. Themis Bio. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gujarat Themis Biosyn Ltd

₹ 325 0.43%
13 Dec - close price
gtbl.in BSE: 506879
About

Incorporated in 1981, Gujarat Themis Biosyn
Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]

Key Points

Business Overview[1][2]
Company manufactures pharmaceuticals and medicinal chemicals. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and became India’s first Company to start commercial production of the Anti-tuberculosis drug Rifampicin.

Website BSE
  • Market Cap ₹ 3,545 Cr.
  • Current Price ₹ 325
  • High / Low ₹ 390 / 108
  • Stock P/E 67.3
  • Book Value ₹ 20.5
  • Dividend Yield 0.20 %
  • ROCE 45.0 %
  • ROE 33.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 56.0% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 41.4%
  • Company has been maintaining a healthy dividend payout of 20.8%
  • Company's working capital requirements have reduced from 101 days to 53.3 days

Cons

  • Stock is trading at 15.9 times its book value
  • Promoter holding has decreased over last 3 years: -4.13%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE Allcap BSE SmallCap BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
35 19 29 45 48 28 28 50 40 39 42 39 35
17 9 16 22 23 16 13 26 23 21 21 20 19
Operating Profit 18 10 13 23 24 12 14 24 17 17 21 19 15
OPM % 53% 53% 45% 51% 51% 43% 52% 47% 42% 45% 50% 48% 44%
1 1 2 1 1 2 2 1 1 1 1 1 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 18 10 14 24 25 13 16 24 17 18 21 18 14
Tax % 25% 26% 29% 25% 26% 26% 25% 26% 26% 26% 24% 26% 26%
14 7 10 18 19 10 12 18 13 13 16 13 11
EPS in Rs 1.27 0.65 0.90 1.63 1.72 0.90 1.07 1.63 1.15 1.19 1.46 1.21 0.97
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
28 30 31 33 36 39 41 85 91 115 148 170 154
25 24 25 27 30 33 34 53 50 57 75 91 82
Operating Profit 3 6 7 6 6 6 7 32 40 58 74 79 72
OPM % 11% 21% 21% 19% 17% 16% 18% 37% 45% 51% 50% 46% 47%
0 0 -0 0 0 0 2 2 3 4 7 4 3
Interest 1 1 0 0 0 0 0 1 1 1 0 0 0
Depreciation 1 1 1 1 1 1 1 1 2 2 3 4 4
Profit before tax 1 5 5 5 5 5 8 31 41 59 77 79 71
Tax % 0% 0% 0% 0% 10% 20% 22% 24% 26% 26% 25% 25%
1 5 5 5 4 4 6 24 30 44 58 59 53
EPS in Rs 0.10 0.42 0.42 0.42 0.40 0.36 0.59 2.17 2.77 4.00 5.32 5.43 4.83
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 10% 0% 37% 14% 12%
Compounded Sales Growth
10 Years: 19%
5 Years: 33%
3 Years: 23%
TTM: 6%
Compounded Profit Growth
10 Years: 29%
5 Years: 56%
3 Years: 25%
TTM: 2%
Stock Price CAGR
10 Years: 60%
5 Years: 120%
3 Years: 70%
1 Year: 162%
Return on Equity
10 Years: %
5 Years: 45%
3 Years: 41%
Last Year: 34%

Balance Sheet

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 7 7 7 7 7 7 7 7 7 7 7 7 11
Reserves -17 -13 -8 -3 1 5 11 35 63 96 142 194 213
11 9 6 3 4 1 6 8 5 1 0 3 3
17 13 9 8 9 8 8 14 14 18 17 17 21
Total Liabilities 18 16 15 15 21 20 33 64 88 122 166 221 248
12 11 10 9 11 11 15 17 19 19 33 38 42
CWIP 0 0 0 0 0 0 1 0 2 13 21 91 136
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
6 5 5 5 11 10 17 47 67 90 113 92 69
Total Assets 18 16 15 15 21 20 33 64 88 122 166 221 248

Cash Flows

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 4 3 4 3 6 1 1 11 40 39 64
-3 -0 -0 -1 -3 -1 -6 -3 -2 -30 -20 -55
2 -3 -3 -3 -0 -4 5 2 -5 -14 -13 -9
Net Cash Flow -0 1 -1 -0 0 1 0 -0 3 -4 6 0

Ratios

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 37 15 28 24 71 26 52 87 59 80 44 58
Inventory Days 58 78 194 144 255 201 33
Days Payable 1,498 947 240 84 145 131 99
Cash Conversion Cycle -1,403 15 28 24 71 -844 52 41 119 189 114 -7
Working Capital Days -172 -128 -76 -69 -30 -43 -58 42 96 158 92 53
ROCE % 208% 121% 81% 55% 42% 45% 84% 67% 67% 61% 45%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
74.99% 74.99% 74.99% 75.00% 75.00% 75.00% 75.00% 75.00% 70.87% 70.87% 70.87% 70.87%
0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.86% 1.05% 1.44% 1.49%
0.31% 0.31% 0.31% 0.03% 0.03% 0.03% 0.03% 0.03% 0.04% 0.82% 1.18% 1.17%
24.70% 24.70% 24.69% 24.98% 24.96% 24.95% 24.95% 24.96% 28.23% 27.26% 26.52% 26.47%
No. of Shareholders 13,05913,91713,83014,90416,55016,80417,37319,84628,65529,57630,28031,271

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls